Olsalazine Sodium (C09-0997-857)

InformationOlsalazine Sodium is an anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond.In vitroOlsalazine displays multiple effects on intestinal electrolyte. In vitro application of Olsalazine (< 2.89 mM) increases the secretion of both sodium and chloride ions and decreases chloride ion absorption in rat and rabbit ileal mucosa. Concentration of Olsalazine < 11.5 mM also dose-dependently decreases net sodium and, to a greater degree, chloride absorption in the isolated rat colon. Potassium secretion is also increases but only at a high Olsalazine concentration (11.5 mM). Olsalazine also inhibits absorption of glucose and lactose in isolated rat jejunum. Olsalazine is potent inhibitors of human intestinal macrophages chemotaxis to LTB4 with IC50 of 0.39 mM. Olsalazine (0.4 mM) inhibits the superoxide radical production generated by phorbol myristate acetate (PMA)-activated neutrophils or by xanthine-xanthine oxidase reaction by reduction of 31% and 73%, respectively. Other suggested possible mechanisms by which Olsalazine-derived mesalazine might ameliorate colonic mucosa/inflammation are inhibition of platelet activating factor, inhibition of cytokine production in human mononuclear cells, suppression of colonic fatty acid oxidation, inhibition of endothelial cell proliferation by folic acid antagonism, inhibition of leukotriene synthesis from arachidonic acid via inhibition of lipoxygenase, modulation of the prostaglandin profile by an effect on prostaglandin 15-hydroxydehydrogenase, and interference with leukocyte function.In vivoOlsalazine is developed as a way of delivering mesalazine to the colon, since very little of parent molecule is absorbed from the gastrointestinal tract following oral administration. In the colon, azoreductase bacteria cleave the azo bond, releasing 2 molecules of mesalazine which has demonstrated therapeutic effect in inflammatory bowel diseases. Olsalazine (50mg/kg/day) significantly prolongs the survival of nu/nu CD-1 mice with experimental colitis induced by dextran sulphate sodium. Olsalazine inhibits tumor growth in a rodent model of colorectal cancer. In 1,2-dimethylhydrazine-treated rats, Olsalazine (25 mg/kg/day) decreases number and volume of tumors by 58.17% and 62.67%, respectively. Administration of Olsalazine induces a 1.7-fold times increase in the number of apoptotic cells, companied with a reduction of 42.4% in cell proliferation rate.Cell Datacell lines：Concentrations：Incubation Time：Powder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C14H8N2O6·2Na Molecular Weight: 346.2